Caspase-dependent apoptosis induced by telomere cleavage and TRF2 loss.
Chromosomal abnormalities involving telomeric associations (TAs) often precede replicative senescence and abnormal chromosome configurations. We report here that telomere cleavage following exposure to proapoptotic agents is an early event in apoptosis. Exposure of human and murine cancer cells to a variety of pro-apoptotic stimuli (staurosporine, thapsigargin, anti-Fas antibody, and cancer chemotherapeutic agents) resulted in telomere cleavage and aggregation, and finally their extrusion from the nuclei. Telomere loss was associated with arrest of cells in G2/M phase and preceded DNA fragmentation. Telomere erosion and subsequent large-scale chromatin cleavage were inhibited by overexpression of the anti-apoptotic protein, bcl-2, and two peptide caspase inhibitors (BACMK and zVADfmk), indicating that both events are regulated by caspase activation. The results demonstrate that telomere cleavage is an early chromatin alteration detected in various cancer cell lines leading to drug-induced apoptosis, and suggest that this event contributes to mitotic catastrophe and induction of cell death. Results also suggest that the decrease of telomeric-repeat binding factor 2 (TRF2) may be the earliest event in the ara-C-induced telomere shortening, induction of endoreduplication and chromosomal fragmentation leading to cell death.
Multani
A S
AS
Department of Cancer Biology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Ozen
M
M
Narayan
S
S
Kumar
V
V
Chandra
J
J
McConkey
D J
DJ
Newman
R A
RA
Pathak
S
S
D000818:Animals; D017209:Apoptosis; D020169:Caspases / Q000378:metabolism*; D002869:Chromosome Aberrations; D002999:Clone Cells; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology*; D003561:Cytarabine / Q000633:toxicity; D004268:DNA-Binding Proteins / Q000378:metabolism*; D019254:Genes, bcl-2; D006801:Humans; D008546:Melanoma, Experimental; D051379:Mice; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D016615:Telomere / Q000187:drug effects / Q000378:metabolism*; D035341:Telomeric Repeat Binding Protein 2; D014162:Transfection; D014407:Tumor Cells, Cultured
D015853:Cysteine Proteinase Inhibitors; D004268:DNA-Binding Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D035341:Telomeric Repeat Binding Protein 2; D003561:Cytarabine; D020169:Caspases